Association of Metformin Pharmacogenetic with a Single Amino Acid Alteration in Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Genein Patients with Polycystic Ovary Syndrome

Polycystic ovarian syndrome (PCOS) is known as a metabolic, reproductive and ovarian degeneration disorder. Pro12 Ala mutation in peroxisome proliferator-activated receptor gamma (PPARγ) gene as a transcription factor is linked to disorder of glucose and infertility. In the patients with type 2 diabetes and polycystic ovary syndrome, metformin is the recommended first-line treatment. The aim of this study was evaluation of pharmacokinetics of metformin and the patients genotype for Pro12 Ala polymorphism.

In this study, 100 women with PCOS and 100 healthy women were evaluated. Plasma levels of the FSH and LH were evaluated before and after metformin consumption in the patients.The Pro12 Ala polymorphism was detected by PCR-RFLP analysis.

Two patients carried GG homozygous recessive. There was no significant difference in genotypes between the healthy and patient women. There was a significant difference in plasma levels of LH, FSH and testosterone before and after treatment with metformin but there was no relationship between genotype and response to metformin (p-value = 0.59).

Considering to this research, there is no relationship between Pro12 Ala polymorphism and metformin response in the patients, but the response to metformin for the regulation and improvement ovulation hormones in many patients is satisfactory.